Editorial comment

Editorial

Mack Roach 3rd. J Urol. 2010 Feb.

. 2010 Feb;183(2):551.

doi: 10.1016/j.juro.2009.10.107. Epub 2009 Dec 14.

No abstract available

Comment on

Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation.
Stock RG, Yalamanchi S, Hall SJ, Stone NN. Stock RG, et al. J Urol. 2010 Feb;183(2):546-50. doi: 10.1016/j.juro.2009.10.006. Epub 2009 Dec 14. J Urol. 2010. PMID: 20006854

Editorial comment.
Pinkawa M. Pinkawa M. J Urol. 2010 Feb;183(2):639; discussion 639-40. doi: 10.1016/j.juro.2009.09.092. Epub 2009 Dec 16. J Urol. 2010. PMID: 20018310 No abstract available.
Editorial comment.
Williams SG. Williams SG. J Urol. 2010 Feb;183(2):639; discussion 639-40. doi: 10.1016/j.juro.2009.09.093. Epub 2009 Dec 16. J Urol. 2010. PMID: 20018309 No abstract available.
Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?
Miyamoto H, Messing EM, Chang C. Miyamoto H, et al. Nat Clin Pract Oncol. 2005 May;2(5):236-7. doi: 10.1038/ncponc0168. Nat Clin Pract Oncol. 2005. PMID: 16264955 No abstract available.
Prostate cancer: non-metastatic.
Wilt T. Wilt T. Clin Evid. 2002 Jun;(7):812-23. Clin Evid. 2002. Update in: Clin Evid. 2003 Jun;(9):973-85. PMID: 12230707 Updated. Review. No abstract available.
Prostate cancer (non-metastatic).
Wilt T. Wilt T. Clin Evid. 2003 Jun;(9):973-85. Clin Evid. 2003. Update in: Clin Evid. 2003 Dec;(10):1023-38. PMID: 12967402 Updated. Review. No abstract available.